Quick Order

PLAUR/CD87  Protein, Antibody, ELISA Kit, cDNA Clone

Description: Active  
Expression host: Human Cells  
10925-H08H-200
10925-H08H-100
200 µg 
100 µg 
Add to Cart
  • Slide 1
Expression host: Human Cells  
50160-M08H-50
50160-M08H-20
50 µg 
20 µg 
Add to Cart
  • Slide 1
Description: Active  
Expression host: Human Cells  
50160-M03H-200
50160-M03H-100
200 µg 
100 µg 
Add to Cart
  • Slide 1

PLAUR/CD87 Related Area

PLAUR/CD87 Related Pathways

    PLAUR/CD87 Summary & Protein Information

    PLAUR/CD87 Background

    Gene Summary: PLAUR gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined. [provided by RefSeq, Jul 2008]
    General information above from NCBI
    Subunit structure: Monomer (Probable). Interacts with MRC2. Interacts (via the UPAR/Ly6 domains) with SRPX2. Interacts with SORL1. Interacts with FAP (seprase); the interaction occurs at the cell surface of invadopodia membrane. {ECO:0000269|PubMed:10636902, ECO:0000269|PubMed:12376466, ECO:0000269|PubMed:14764453, ECO:0000269|PubMed:15861141, ECO:0000269|PubMed:16456079, ECO:0000269|PubMed:18718938, ECO:0000269|PubMed:22285761, ECO:0000305}.
    Subcellular location: Cell membrane {ECO:0000269|PubMed:12376466}. Cell projection, invadopodium membrane {ECO:0000269|PubMed:12376466}. Note=Colocalized with FAP (seprase) preferentially at the cell surface of invadopodia membrane in a cytoskeleton-, integrin- and vitronectin-dependent manner. {ECO:0000269|PubMed:12376466}.; Isoform 1: Cell membrane; Lipid-anchor, GPI-anchor.; Isoform 2: Secreted {ECO:0000305}.
    Tissue specificity: Expressed in neurons of the rolandic area of the brain (at protein level). Expressed in the brain.
    Sequence similarity: Contains 3 UPAR/Ly6 domains. {ECO:0000305}.
    General information above from UniProt

    Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.

    PLAUR/CD87 Alternative Name

    PLAUR/CD87 Related Studies

  • Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
  • Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
  • Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
  • Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.
  • Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"